Assoc Prof Dr. RAFİYE CİFTCİLER - Targeted Cancer Therapy - Best Review Article Award

SELCUK UNIVERSITY FACULTY OF MEDICINE DEPARTMENT OF HEMATOLOGY -Turkey

AUTHOR PROFILE

EARLY ACADEMIC PURSUITS:

Rafıye Ciftciler embarked on her academic journey with a strong foundation in medicine and a focus on hematology. She pursued her Medical School education at Hacettepe University Faculty of Medicine, where she laid the groundwork for her future contributions to the field.

PROFESSIONAL ENDEAVORS:

Following her medical education, Rafıye Ciftciler delved into Internal Medicine at Gazi University Faculty of Medicine, broadening her clinical expertise. Subsequently, she specialized in Hematology at Hacettepe University Faculty of Medicine, honing her skills in the intricate field of blood disorders.

CONTRIBUTIONS AND RESEARCH FOCUS ON TARGETED CANCER THERAPY

Rafıye Ciftciler has significantly contributed to the science of hematology, with approximately 100 publications to her name. Her research encompasses a diverse range of topics within hematology, showcasing her dedication to advancing knowledge in the field.

IMPACT AND INFLUENCE:

Her impact extends beyond publications, as evidenced by her accolades. The Young Researcher Award from the Turkish Society of Hematology at the 44th National Hematology Congress and the Oral Presentation Award at the 3rd National Blood and Bone Marrow Transplant Congress underscore her influence in the academic and scientific community.

ACADEMIC CITES:

Rafıye Ciftciler's work has likely garnered attention within the academic community, reflected in her certifications from esteemed organizations like the European Hematology Association and the Turkish Hematology Association. These certifications affirm her proficiency and recognition in the broader scientific arena.

LEGACY AND FUTURE CONTRIBUTIONS:

As an Associate Professor in the Department of Hematology at Selcuk University Faculty of Medicine, Rafıye Ciftciler has already established a commendable legacy. Her continuous contributions to the science of hematology and her role in shaping the next generation of medical professionals mark her as a key figure in the field.

HIGHLIGHT OF FUTURE CONTRIBUTIONS:

Looking ahead, Rafıye Ciftciler's future contributions are anticipated to further enrich the field of Targeted Cancer Therapy. Whether through groundbreaking research, mentorship, or educational initiatives, her commitment to advancing knowledge and improving patient care is poised to leave a lasting impact on the discipline.

NOTABLE PUBLICATIONS

Efficacy and Safety of Immune Checkpoint Inhibitors in Hematologic Malignancies. 2024

The Effect of Obesity and Body Mass Index on Hematologic Malignancies. 2023

Hereditary thrombocytopenia with familial novel mutation in MYH9 gene: A familial case report. 2023

Immune Thrombotic Thrombocytopenic Purpura in Elderly Patients: The Roles of PLASMIC and French Scores. 2023

EARLY ACADEMIC PURSUITS:

Siim Pauklin embarked on his academic journey with a Bachelor's degree in Molecular and Cell Biology from the University of Tartu in Estonia, earning the distinction of Diploma Cum Laude in 2004. He further pursued his academic interests with a Master's degree in Molecular and Cell Biology at the same institution, completing it with distinction in 2005. His early academic pursuits showcased exceptional dedication and achievement in the field.

PROFESSIONAL ENDEAVORS:

Following his Master's degree, Siim Pauklin expanded his academic horizons with a Ph.D. in Biochemistry and Molecular Biology at University College London / CRUK London Research Institute from September 2005 to October 2009. His Ph.D. research, titled "Regulation of Activation Induced Deaminase (AID)," not only earned him the prestigious Pontecorvo prize for the best thesis in CRUK but also led to groundbreaking discoveries in the regulation of AID expression by hormones and its role in immune responses, autoimmune diseases, and tumorigenesis.

CONTRIBUTIONS AND RESEARCH FOCUS ON TARGETED CANCER THERAPY

Siim Pauklin's research has been instrumental in advancing our understanding of stem cell biology and cancer research, particularly in the molecular mechanisms regulating cancer stem cell formation. His work on the TGFß/Activin/Nodal-SMAD2/3 signaling pathway in pancreatic ductal adenocarcinomas and cancer stem cells has paved the way for insights into chemoresistance, metastatic capacity, and the 3D chromatin architecture of pancreatic cancer.

IMPACT AND INFLUENCE:

Siim Pauklin's impact in the field is evident from his career trajectory, securing prestigious fellowships, awards, and recognition for his significant contributions. His leadership as a Principal Investigator and CRUK Career Development Fellow at the University of Oxford underscores his influence in the scientific community.

LEGACY AND FUTURE CONTRIBUTIONS:

Siim Pauklin's research focus on Targeted cancer therapy and pancreatic cancer. As he continues to lead his research group at the University of Oxford, his commitment to uncovering early detection methods and advancing therapeutic strategies for cancer stem cells promises a lasting impact on the field. His future contributions are anticipated to further shape our understanding of cancer biology and contribute to the development of novel cancer therapies.